Human papillomavirus type 16 and type 18 E7 protein (HPV-16/18 E7)

The Human papillomavirus type 16 and type 18 E7 protein is a multifunctional **viral oncoprotein** critically implicated in HPV-driven oncogenesis, particularly in cervical and other anogenital cancers. It is a 98-amino-acid nuclear phosphoprotein with no intrinsic enzymatic activity, functioning mainly through potent protein-protein interactions. E7 disrupts normal cell cycle control by binding and inactivating the **retinoblastoma tumor suppressor protein (pRB)** and related family members, freeing E2F transcription factors and promoting uncontrolled S-phase entry and proliferation. It also cooperates with viral E6 protein for immortalization of keratinocytes and functions in blocking apoptosis and modulating various cellular pathways. The E7 protein contains conserved regions (CR1 and CR2), akin to adenoviral E1A, and a C-terminal zinc-binding motif that stabilizes its structure and mediates further interactions. Its persistent expression is a hallmark of HPV-induced malignancies, making it an important diagnostic biomarker and a promising, though challenging, target for therapeutic vaccines and novel anticancer interventions[1][2][3][5][6][7][8].

Other names

HPV E7 proteinE7 oncoproteinHPV16 E7HPV18 E7

Inhibition of retinoblastoma protein (pRB) and related tumor suppressors, leading to deregulation of the cell cycle[1][3][5][8]. Destabilization and degradation of pRB by protein-protein interactions[1][3][8]. Promotion of E2F transcription factor release, resulting in S-phase entry and uncontrolled proliferation[2][3][5]. Modulation of apoptotic and anti-apoptotic signaling[7].